# A Hybrid Machine Learning Model for Classifying Gene Mutations in Cancer using LSTM, BiLSTM, CNN, GRU, and GloVe

arXiv: https://arxiv.org/abs/2307.14361 · HTML: https://mlsanity.com/paper/2307.14361/

## Key facts

- Cited by 1 papers in the map (data through 14 Oct 2026).
- Builds on 6 of its 40 references that are in the map.
- First posted on arXiv 24 Jul 2023.

## Builds on (most cited first, 6 of 6)

- [BERT: Pre-training of Deep Bidirectional Transformers for Language Understanding](https://mlsanity.com/paper/1810.04805/) (2018)
- [RoBERTa: A Robustly Optimized BERT Pretraining Approach](https://mlsanity.com/paper/1907.11692/) (2019)
- [DistilBERT, a distilled version of BERT: smaller, faster, cheaper and lighter](https://mlsanity.com/paper/1910.01108/) (2019)
- [XLNet: Generalized Autoregressive Pretraining for Language Understanding](https://mlsanity.com/paper/1906.08237/) (2019)
- [Empirical Evaluation of Gated Recurrent Neural Networks on Sequence Modeling](https://mlsanity.com/paper/1412.3555/) (2014)
- [Bidirectional LSTM-CRF Models for Sequence Tagging](https://mlsanity.com/paper/1508.01991/) (2015)

## Built on by (most cited first, 1 of 1)

- [An Ensemble Approach to Question Classification: Integrating Electra Transformer, GloVe, and LSTM](https://mlsanity.com/paper/2308.06828/) (2023)

## Abstract (arXiv)

In our study, we introduce a novel hybrid ensemble model that synergistically combines LSTM, BiLSTM, CNN, GRU, and GloVe embeddings for the classification of gene mutations in cancer. This model was rigorously tested using Kaggle's Personalized Medicine: Redefining Cancer Treatment dataset, demonstrating exceptional performance across all evaluation metrics. Notably, our approach achieved a training accuracy of 80.6%, precision of 81.6%, recall of 80.6%, and an F1 score of 83.1%, alongside a significantly reduced Mean Squared Error (MSE) of 2.596. These results surpass those of advanced transformer models and their ensembles, showcasing our model's superior capability in handling the complexities of gene mutation classification. The accuracy and efficiency of gene mutation classification are paramount in the era of precision medicine, where tailored treatment plans based on individual genetic profiles can dramatically improve patient outcomes and save lives. Our model's remarkable performance highlights its potential in enhancing the precision of cancer diagnoses and treatments, thereby contributing significantly to the advancement of personalized healthcare.